|
|
PROSTATE, LUNG, COLO-RECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL EXPANSION F
|
N01CN075022-066
|
$1,291,459
|
$322,865
|
Fouad, Mona
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
|
Core Support for Cancer Center
|
3P30CA013330-38S2
|
$100,000
|
$1,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
5P30CA013330-38
|
$3,927,232
|
$39,272
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
2U10CA014958-36
|
$127,404
|
$2,548
|
SPARANO, JOSEPH
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Skp2 in androgen-dependent proliferation of prostate cancer cells
|
5R01CA127901-02
|
$310,005
|
$310,005
|
ZHU, LIANG
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Characterizing Genetic Susceptibility to Breast and Prostate Cancer: The BPC3.
|
5U01CA098710-07
|
$312,578
|
$156,289
|
THUN, MICHAEL
|
AMERICAN CANCER SOCIETY, INC.
|
|
|
Community Clinical Oncology Program
|
2U10CA037422-23
|
$4,179,081
|
$1,671,632
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-34S2
|
$1,198,505
|
$719,103
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S2
|
$28,500
|
$11,400
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S3
|
$1,208,966
|
$483,586
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
RTOG Tissue Bank
|
3U24CA114734-05S1
|
$1,040,063
|
$104,006
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-34
|
$12,451,705
|
$7,471,023
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
American College of Radiology Imaging Network
|
5U01CA080098-12
|
$9,041,302
|
$1,130,163
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
SBIR TOPIC 241 PHASE II: Platelet-based Nanoparticle Therapy for Prostate Cancer
|
N44CO100119-000
|
$999,642
|
$999,642
|
Zwick, Michael
|
ANDROBIOSYS, INC.:1150748
|
|
|
Molecular Target Focused Discovery of Anticancer Drugs
|
5R01CA090441-08
|
$381,250
|
$53,375
|
PETTIT, GEORGE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Nano-Flares for the Intracellular Detection of miRNA in Living Cells
|
1R43CA153624-01
|
$200,000
|
$200,000
|
Giljohann, David
|
AURASENSE, LLC
|
|
|
Modular internalizing molecules for treatment of more than one stage of malignanc
|
1R43CA141725-01A1
|
$183,938
|
$183,938
|
GREENBERG, MICHAEL
|
B3 BIO, INC.
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-21
|
$461,201
|
$64,568
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
Bioflavonoid Effects on EGF Signaling and Cell Cycle Pathways in Prostate Cancer
|
5R01CA128932-02
|
$318,513
|
$318,513
|
MARKAVERICH, BARRY
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
2P30CA125123-04
|
$3,089,219
|
$278,030
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-03S6
|
$100,000
|
$9,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-04S1
|
$250,400
|
$22,536
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
DNA Repair and Replication Re-start in vivo
|
5R01CA085777-07
|
$300,598
|
$30,060
|
Rosenberg, Susan
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
3R01CA058093-17S1
|
$3,631
|
$3,631
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mesenchymal Derived Growth Factors in Prostatic Cancer
|
5R01CA058093-17
|
$269,842
|
$269,842
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Co-evolution of the Reactive Microenvironment in Prostate Cancer Progression
|
5U54CA126568-05
|
$471,453
|
$471,453
|
ROWLEY, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Role of FGFR1 signaling in distinct cell lineages in prostate cancer progresssion
|
5U01CA141497-02
|
$742,690
|
$742,690
|
SPENCER, DAVID
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Reversal of regulatory T cell function in prostate cancer
|
5R01CA121191-05
|
$258,529
|
$258,529
|
Wang, Rongfu
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
3R00CA125937-04S1
|
$51,582
|
$51,582
|
Xin, Li
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Characterization of prostatic stem cells and prostate cancer-initiating cells
|
5R00CA125937-04
|
$249,000
|
$249,000
|
Xin, Li
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-26S1
|
$487,529
|
$73,129
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-12
|
$104,956
|
$2,099
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting AR-NCoR Interaction in Prostate Cancer
|
5R01CA111803-04
|
$323,000
|
$323,000
|
BALK, STEVEN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The Role of PTEN and the PI3K Pathway in Prostate Cancer
|
5P01CA089021-09
|
$2,107,760
|
$2,107,760
|
CANTLEY, LEWIS
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A Platform for Cancer Biomarker Validation: Image Fusion Using NIR Fluorescence
|
5R01CA134493-02
|
$661,011
|
$661,011
|
FRANGIONI, JOHN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A Rigid Multivalent Chemical Platform for Targeted Diagnostics and Therapeutics
|
5F32CA132332-03
|
$55,790
|
$55,790
|
Nasr, Khaled
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
A metabolic role for PML in tumor suppression
|
1R01CA142780-01
|
$360,359
|
$90,090
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of POZ-zinc finger proteins in tumorigenesis.
|
2R01CA102142-06A1
|
$340,356
|
$112,317
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
PTEN and ontogenesis and tumor suppression
|
5R01CA082328-13
|
$351,147
|
$87,787
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting Tumor Suppressor Phosphatases For Cancer Therapy
|
5U01CA141496-02
|
$839,120
|
$839,120
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Harvard/Michigan/Cornell Prostate Cancer Biomarker Clinical Validation Center
|
2U01CA113913-06
|
$756,597
|
$756,597
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
|
3U01CA113913-05S1
|
$233,591
|
$233,591
|
SANDA, MARTIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The function of RhoBTB proteins
|
5R01CA113559-05
|
$293,000
|
$73,250
|
Soltoff, Stephen
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
ERG participates in the cellular response to DNA damage by downregulating CHK1
|
1F32CA142089-01A1
|
$59,918
|
$59,918
|
Varmeh, Shohreh
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Low Cost Microfluidic System for Detection of CTCs
|
N43CO100066-000
|
$199,517
|
$99,759
|
Hupert, Mateusz
|
BIOFLUIDICA MICROTECHNOLOGIES, LLC
|
|
|
Geostatistical software for the analysis of individual-level epidemiologic data
|
5R44CA132347-03
|
$430,798
|
$215,399
|
GOOVAERTS, PIERRE
|
BIOMEDWARE
|
|
|
The MB-CCOP at Boston Medical Center
|
1U10CA139519-01A1
|
$706,684
|
$141,337
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
|
Combination Therapies for Cancer Treatment
|
2R01CA049248-20A1
|
$338,392
|
$169,196
|
WAXMAN, DAVID
|
BOSTON UNIVERSITY
|
|
|
Quantitative Analysis of Tumor Cell Migration in Three Dimensioinal Matrices
|
3R01CA132633-04S1
|
$65,907
|
$65,907
|
Zaman, Muhammad
|
BOSTON UNIVERSITY
|
|
|
Quantitative Analysis of Tumor Cell Migration in Three Dimensioinal Matrices
|
5R01CA132633-04
|
$250,351
|
$250,351
|
Zaman, Muhammad
|
BOSTON UNIVERSITY
|
|
Total relevant funding to Prostate for this search: $300,466,914
|
